PITTSBURGH, Oct 27, 2010 /PRNewswire via COMTEX News Network/ -- In the news release, Third Circuit Denies Mylan Motion for Interim Injunction, issued 27-Oct-2010 by Mylan Inc. over PR Newswire, we are advised by the company that the first paragraph contained some missing information. The first sentence should include the phrase, "relating to generic Paroxetine CR" after "New Jersey District Court decision." The sub-headline has also been amended. The complete, corrected release follows:

Mylan Inc. (Nasdaq: MYL) today announced that the Third Circuit Court of Appeals denied its motion for an interim injunction pending an on-going appeal of a recent New Jersey District Court decision relating to generic Paroxetine CR. The New Jersey District Court previously denied Mylan's motion for a preliminary injunction, and the appeal of that decision will now continue before the Third Circuit. Mylan is disappointed by the decision, which does not reflect a final decision on the merits of Mylan's claims, and Mylan will continue to pursue its claims.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.

Copyright (C) 2010 PR Newswire. All rights reserved